Charles River Laboratories International (CRL)

NYSE Markedet er stengt

Charles River Laboratories International, Inc. er et selskap som tilbyr kontraktsforskning og produksjonsstøtte til markedene for legemidler, bioteknologi, medisinsk utstyr, akademisk forskning og offentlig forskning. Selskapet ble grunnlagt i 1947 og spiller en sentral rolle i det outsourcade livsvitenskapsøkosystemet ved å hjelpe kunder med å føre potensielle terapier fra tidlig forskning gjennom preklinisk utvikling og kvalitetstesting.

Selskapet er best kjent for sine forskningsmodeller og tilhørende tjenester. Charles River leverer laboratoriedyrmodeller med definerte genetiske og helsemessige egenskaper, sammen med spesialiserte tjenester som støtter prekliniske studier. Disse modellene brukes av forskere til å studere sykdomsbiologi, evaluere legemiddelkandidater og generere data før kliniske studier på mennesker starter.

Utover forskningsmodeller tilbyr Charles River tjenester innen discovery og sikkerhetsvurdering. Denne delen av selskapet støtter legemiddelutviklere med aktiviteter som målvalidering, farmakologi, toksikologi og andre studier som kreves for å vurdere om en forbindelse er egnet for videre utvikling. Ved å tilby disse tjenestene eksternt gir selskapet kundene tilgang til vitenskapelig ekspertise og infrastruktur uten å måtte bygge opp all kapasitet internt.

Charles River driver også et segment for produksjonsstøtte som omfatter produkter for mikrobiell testing, testtjenester for biologiske legemidler og tjenester knyttet til fuglevaksiner. Disse tilbudene hjelper kundene med å bekrefte produktsikkerhet, kvalitet og regulatorisk etterlevelse, særlig innen biologiske legemidler og avanserte terapier.

Selskapets posisjon er særpreget fordi det dekker flere stadier i forsknings- og utviklingsprosessen. Kundene er avhengige av selskapet ikke bare for laboratoriemodeller, men også for vitenskapelige tjenester og kvalitetskontrollverktøy som er integrert i arbeidsflyter for legemiddeloppdagelse, preklinisk testing og bioproduksjon.

179.87 USD
176.00 USD
+5.08 (+2.91%)
Etter stengetid

Sist oppdatert

Markedsverdi
8.42B
P/E-tall
P/FCF-tall
28.38
P/S-tall
2.09
Selskapsverdi
10.89B
Sektor
Industrials
Bransje
Commercial Physical and Biological Research
Adresse
251 BALLARDVALE ST, WILMINGTON, MA, 01887
GlobeNewswire Inc.

Cell Banking Outsourcing Market: 16%+ CAGR (2026-2031), Expanding with Rising Demand for Biologics and Regenerative Medicine Services, Says Mordor Intelligence

25. mai 2026, 10:15 A.M.
GlobeNewswire Inc.

Global Plasmid DNA Manufacturing Market Anticipates Impressive Growth Trajectory at a CAGR of ~18% by 2034 | DelveInsight

04. mai 2026, 19:00 P.M.
GlobeNewswire Inc.

Global AAV Vector Manufacturing Market Gearing Up for Outstanding Expansion at a CAGR of ~22% by 2034 | DelveInsight

28. apr. 2026, 19:00 P.M.
GlobeNewswire Inc.

Drug Development Services Market Research Report 2026: $50+ Bn Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F

14. apr. 2026, 16:59 P.M.
GlobeNewswire Inc.

Practical Implementation of GCP in Veterinary Course: Approaches to the Design, Set-up and Conduct in Compliance with VICH Good Clinical Practice (GCP) Principles (ONLINE EVENT: May 13th-14th, 2026)

14. apr. 2026, 10:58 A.M.
GlobeNewswire Inc.

[Latest] Global Pharmaceutical Microbiology QC Testing Market Size/Share Worth USD 17.65 Billion by 2035 at a 13.27% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, SWOT Analysis)

10. mars 2026, 19:00 P.M.
GlobeNewswire Inc.

[Latest] Global Adeno Associated Virus Vector Manufacturing Market Size/Share Worth USD 9.87 Billion by 2035 at a 13.4% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Growth Rate, Value, SWOT Analysis)

03. feb. 2026, 19:00 P.M.
GlobeNewswire Inc.

Lead Optimization Services in Drug Discovery Market to Reach USD 10.26 Billion by 2034, Driven by Rising R&D Activity

28. nov. 2025, 16:00 P.M.
GlobeNewswire Inc.

Innovative Drug CRO Market to Soar USD 96.06 Billion by 2035, Expanding at 5.44% CAGR

28. nov. 2025, 15:00 P.M.
GlobeNewswire Inc.

Cell-based Assays Market Size to Reach USD 35.34 Billion by 2032, Driven by Demand for Drug Discovery and Advanced Biotechnology Research – SNS Insider

30. okt. 2025, 09:59 A.M.
GlobeNewswire Inc.

Cell & Gene Therapy Quality Control Market Poised USD 22.81 Billion at 25.74% CAGR by 2034

29. okt. 2025, 14:00 P.M.
GlobeNewswire Inc.

Biologics Safety Testing Market to Rise at 13.64% CAGR, Soars USD 14.45 Bn by 2034

16. okt. 2025, 17:00 P.M.
GlobeNewswire Inc.

Pharmaceutical Contract Research Services Market Report 2025-2035: M&A, Partnerships, and Biologics Focus

24. sep. 2025, 10:53 A.M.
GlobeNewswire Inc.

Global Bioanalytical Testing Services Market to Observe Stunning Growth at a CAGR of ~16% by 2032 | DelveInsight

26. aug. 2025, 19:00 P.M.
GlobeNewswire Inc.

Clinical Trial Biorepository and Archiving Solutions Market Size Expected to Attain USD 9.69 Billion by 2034

19. aug. 2025, 17:00 P.M.
GlobeNewswire Inc.

Residual DNA Testing Global Market Forecast to 2030 | Novel Modalities, Emerging Markets Growth, Continuous Processing Integration, and Rising CRO/CDMO Outsourcing

05. aug. 2025, 10:35 A.M.
GlobeNewswire Inc.

Pharma Contract Research Organization (CRO) Services Market to Cross USD 36.66 Billion in 2025, Expanding at a CAGR of 10.04%

18. juli 2025, 16:00 P.M.
GlobeNewswire Inc.

Preclinical CRO Market Size at USD 6.8 Billion in 2025, Forecasted to Grow at 8.73% CAGR Through 2034

16. juli 2025, 16:00 P.M.
GlobeNewswire Inc.

Regulatory Affairs Outsourcing Market Analysis Report 2025: Globalization of Biopharmaceutical and Medical Device Companies Bolster Growth - Trends, Opportunities, and Forecasts 2020-2030

05. juni 2025, 10:57 A.M.
GlobeNewswire Inc.

Cell-Based Assays: The Future of Biomedical Breakthroughs

02. mai 2025, 20:44 P.M.
Markedsverdi
8.42B
Selskapsverdi
10.89B
P/E-tall
P/B-tall
2.86
P/S-tall
2.09
EV / EBITDA-forhold
13.67
EV / omsetning
2.7
Resultat per aksje
-3.83
Utbytterente
0%
P/FCF-tall
28.38
P/CF-tall
13.87
Fri kontantstrøm
296.67M
Avkastning på egenkapital
-6.28%
Avkastning på eiendeler
-2.39%
Gjeld / egenkapital
0.91
Likviditetsgrad I
1.36
Likviditetsgrad II
1.03
Kontanter
0.18
Snittvolum
925.56K
Fundamentalpris (snapshot)
174.79

Resultatregnskap

Post 2026 Q1 2025 Q4 2025 Q3 2025 Q2 2025 Q1
Omsetning 995.83M 994.23M 1B 1.03B 984.17M
Bruttofortjeneste 294.66M 309.68M 338.79M 357.07M 317.73M
Driftsresultat 119.9M -283.44M 133.8M 100.13M 74.67M
Driftsresultat før avskrivninger (EBITDA) 187.05M 170.81M 218.96M 219.64M 195.03M
Nettoresultat -14.84M -276.56M 54.42M 52.33M 25.47M
Grunnleggende EPS -0.3 -5.57 1.11 1.06 0.5
Utvanet EPS -0.3 -5.56 1.1 1.06 0.5

Balanse

Post 2026 Q1 2025 Q4 2025 Q3 2025 Q2 2025 Q1
Sum eiendeler 7.73B 7.14B 7.51B 7.56B 7.58B
Sum gjeld 4.74B 3.92B 4.06B 4.16B 4.34B
Egenkapital 2.95B 3.17B 3.41B 3.36B 3.2B
Kontanter og ekvivalenter 191.83M 213.77M 207.1M 182.82M 229.36M
Omløpsmidler 1.49B 1.45B 1.53B 1.47B 1.51B
Kortsiktig gjeld 1.09B 1.12B 1.12B 1.08B 1.05B

Kontantstrøm

Post 2026 Q1 2025 Q4 2025 Q3 2025 Q2 2025 Q1
Kontantstrøm fra drift 41.08M 147.52M 213.83M 204.6M 171.7M
Kontantstrøm fra investeringer -407.85M -92.81M -33.7M -37.34M -45.48M
Kontantstrøm fra finansiering 347.72M -51.86M -152.62M -226.92M -105.33M
Endring i kontanter -17.8M 6.78M 24.48M -46.99M 26.16M
Type Rapport Dato Lenke
edgar index 4 — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Vis rapport
edgar index 4 — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Vis rapport
edgar index 4 — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Vis rapport
edgar index 4 — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Vis rapport
edgar index 4 — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Vis rapport
edgar index 4 — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Vis rapport
edgar index 4 — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Vis rapport
edgar index 4 — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Vis rapport
edgar index 4 — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Vis rapport
edgar index 4 — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Vis rapport
form 4 Form 4 — Andrews Nancy C Vis rapport
form 4 Form 4 — Andrews Nancy C Vis rapport
edgar index SD — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Vis rapport
edgar index 8-K — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Vis rapport
edgar index 4 — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Vis rapport
edgar index 4 — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Vis rapport
edgar index 4 — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Vis rapport
edgar index 4 — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Vis rapport
edgar index 4 — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Vis rapport
edgar index 4 — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Vis rapport
edgar index 4 — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Vis rapport
edgar index 4 — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Vis rapport
eight k text 8-K — 8-K Vis rapport
form 4 Form 4 — FOSTER JAMES C Vis rapport
form 4 Form 4 — FOSTER JAMES C Vis rapport
form 4 Form 4 — FOSTER JAMES C Vis rapport
form 4 Form 4 — FOSTER JAMES C Vis rapport
form 4 Form 4 — FOSTER JAMES C Vis rapport
form 4 Form 4 — FOSTER JAMES C Vis rapport
form 4 Form 4 — FOSTER JAMES C Vis rapport
form 4 Form 4 — FOSTER JAMES C Vis rapport
form 4 Form 4 — WILSON VIRGINIA M Vis rapport
form 4 Form 4 — Kemps-Polanco Reshema Vis rapport
form 4 Form 4 — Kemps-Polanco Reshema Vis rapport
form 4 Form 4 — Enyedy Mark J Vis rapport
form 4 Form 4 — Llado George Sr. Vis rapport
form 4 Form 4 — Llado George Sr. Vis rapport
form 4 Form 4 — Andrews Nancy C Vis rapport
form 4 Form 4 — MACKAY MARTIN Vis rapport
form 4 Form 4 — MACKAY MARTIN Vis rapport
form 4 Form 4 — Ceesay Abraham Vis rapport
form 4 Form 4 — Graves Paul W Vis rapport
form 4 Form 4 — Thompson Craig B. Vis rapport
form 4 Form 4 — Barg Steven Vis rapport
edgar index S-8 — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Vis rapport
edgar index 8-K — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Vis rapport
edgar index 10-Q — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Vis rapport
eight k text 8-K — 8-K Vis rapport
edgar index SCHEDULE 13G — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Vis rapport
edgar index SCHEDULE 13G/A — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Vis rapport
edgar index 4 — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Vis rapport
form 4 Form 4 — Coleman Glenn Vis rapport
edgar index SCHEDULE 13G — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Vis rapport
edgar index 3 — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Vis rapport
form 3 Form 3 — Coleman Glenn Vis rapport
edgar index SCHEDULE 13G/A — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Vis rapport
edgar index 4 — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Vis rapport
edgar index 4 — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Vis rapport
edgar index 4 — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Vis rapport
form 4 Form 4 — Girshick Birgit Vis rapport
form 4 Form 4 — Girshick Birgit Vis rapport
form 4 Form 4 — LaPlume Joseph W Vis rapport
form 4 Form 4 — FOSTER JAMES C Vis rapport
form 4 Form 4 — FOSTER JAMES C Vis rapport
form 4 Form 4 — FOSTER JAMES C Vis rapport
form 4 Form 4 — FOSTER JAMES C Vis rapport
form 4 Form 4 — FOSTER JAMES C Vis rapport
form 4 Form 4 — FOSTER JAMES C Vis rapport
form 4 Form 4 — FOSTER JAMES C Vis rapport
edgar index 8-K — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Vis rapport
eight k text 8-K — 8-K Vis rapport
edgar index 8-K — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Vis rapport
edgar index 8-K — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Vis rapport
edgar index 10-K — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Vis rapport
eight k text 8-K — 8-K Vis rapport